Rupert Lewis

Rupert Lewis, CEO of Oyster Venture Partners, leads an investment intermediary dedicated to the healthcare innovation sector across four verticals – Drug, Diagnostic, Device and Digital.

Working in close association with the Alliance Manchester Business School, Oyster was incorporated in 2019 together with David D’Alton, representing a merger of two similar businesses now comprising a team of 12 tier-1-experienced healthcare and investment professionals based in the UK (London and Manchester) and in the EU (Belgium), backed by a 25-strong Scientific Advisory Board.

Together with its many ecosystem channel partners in the UK, EU, North America and Australia, Oyster supports healthcare start-/scale-ups through successive investment rounds, enabling innovators to concentrate on their core bench side-to-bedside innovation pathway.  Oyster’s main focus centres on providing support for scientists and technologists to convert their science/tech-oriented pitches into pre-due diligenced investment propositions that are meaningful to investors.  At the forefront of the investment-in-innovation process, Oyster increases the predictability of successful financing for its clients whilst also seeking to develop innovative support solutions, such as their recent valuation of data assets service, that is part of the portfolio of offerings that seeks to remove investment resistance.